Loading…
Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France
To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months). We conducted a national register-based study by extracting all reimburs...
Saved in:
| Published in: | Contraception (Stoneham) 2022-04, Vol.108, p.50-55 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93 |
| container_end_page | 55 |
| container_issue | |
| container_start_page | 50 |
| container_title | Contraception (Stoneham) |
| container_volume | 108 |
| creator | Roland, Noémie Drouin, Jérôme Desplas, David Duranteau, Lise Cuenot, François Dray-Spira, Rosemary Weill, Alain Zureik, Mahmoud |
| description | To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months).
We conducted a national register-based study by extracting all reimbursements of oral contraceptives (OC), emergency contraception (EC), intrauterine devices (IUD), and implants from the French National Health Insurance database (SNDS), which includes and covers 99.5% of the French population, in 2018, 2019, 2020 and from January 1, 2021 to April30, 2021. We calculated the expected use of contraceptives in 2020 and 2021 in the absence of the pandemic, based on 2018 and 2019 usage and taking annual trends into account. We assessed the difference between observed and expected dispensing rates by contraceptive type and by age-group (≤18 years old, 18< age ≤25, 25< age ≤35, >35).
Dispensing of all contraceptives decreased compared to expect dispensing numbers: −2.0% for OC, −5.3% for EC, −9.5% for LNG-IUS, −8.6% for C-IUD, and −16.4% for implant. This decrease in the dispensing of contraceptives was observed in all age-groups, but mainly concerned women under the age of 18 years (−22% for OC, −10% for EC, −37.2% for LNG-IUS, −36.4% for C-IUD, −26.4% for implant) and those aged 18 to 25 (−5.1% for OC, −11.9% for EC, −18.1% for LNG-IUS, −15.9% for C-IUD, −17.6% for implants).
Our study showed that the dispensing of contraceptives in France was markedly impacted by the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under the age of 25 years were the most substantially impacted. Ensuring access to contraceptive methods during health emergencies must be a public health policy priority.
The COVID-19 pandemic strongly impacted the dispensing of contraceptives in France with varying degrees of decreased dispensing according to the type of contraceptive, the age-group and the level of pandemic-related restrictions. The impact of these restrictions on unintended pregnancy at the population level remains undetermined. |
| doi_str_mv | 10.1016/j.contraception.2021.12.002 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8714238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010782421004649</els_id><sourcerecordid>2615917452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS0EotvCX0CWuLSHBNuJk1hISKulpSut1Atwtbz2mPUqawc7WcS_x9G2FcuJk6XxN2_evEHoPSUlJbT5sC918GNUGobRBV8ywmhJWUkIe4EWtGtFQTjtXqIFIZQUbcfqC3SZ0p4Q0grevkYXVS1a2pBqgX6tD4PSIw4Wr0IMXh1dnBI2LoFKgBmhAl-vHr6vPxdU3ODg8dlwPGXI-cwxgpU3eBrw5EfX43EHGHIhCy-HmAuzzRm9i8preINeWdUnePv4XqFvd7dfV_fF5uHLerXcFJozPhbQdZZshRBcaW1ry41VljYmL2KqCnStVWNpXTMmDFFagNLUqJYLsBy2RlRX6NNJd5i2BzAaZvO9zI4OKv6WQTl5_uPdTv4IR9m1tGZVlwVuTgK7f9rulxs510jVtFXD2ZFm9vpxWAw_J0ijPLikoe-VhzAlyRrKBW1rzjL68YTqGFKKYJ-1KZHzmeVeniUt5_wkZTKfOXe_-3ur596nu2bg9gRAzvboIMqkHeTcjYugR2mC-69BfwCE7L_V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2615917452</pqid></control><display><type>article</type><title>Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Roland, Noémie ; Drouin, Jérôme ; Desplas, David ; Duranteau, Lise ; Cuenot, François ; Dray-Spira, Rosemary ; Weill, Alain ; Zureik, Mahmoud</creator><creatorcontrib>Roland, Noémie ; Drouin, Jérôme ; Desplas, David ; Duranteau, Lise ; Cuenot, François ; Dray-Spira, Rosemary ; Weill, Alain ; Zureik, Mahmoud</creatorcontrib><description>To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months).
We conducted a national register-based study by extracting all reimbursements of oral contraceptives (OC), emergency contraception (EC), intrauterine devices (IUD), and implants from the French National Health Insurance database (SNDS), which includes and covers 99.5% of the French population, in 2018, 2019, 2020 and from January 1, 2021 to April30, 2021. We calculated the expected use of contraceptives in 2020 and 2021 in the absence of the pandemic, based on 2018 and 2019 usage and taking annual trends into account. We assessed the difference between observed and expected dispensing rates by contraceptive type and by age-group (≤18 years old, 18< age ≤25, 25< age ≤35, >35).
Dispensing of all contraceptives decreased compared to expect dispensing numbers: −2.0% for OC, −5.3% for EC, −9.5% for LNG-IUS, −8.6% for C-IUD, and −16.4% for implant. This decrease in the dispensing of contraceptives was observed in all age-groups, but mainly concerned women under the age of 18 years (−22% for OC, −10% for EC, −37.2% for LNG-IUS, −36.4% for C-IUD, −26.4% for implant) and those aged 18 to 25 (−5.1% for OC, −11.9% for EC, −18.1% for LNG-IUS, −15.9% for C-IUD, −17.6% for implants).
Our study showed that the dispensing of contraceptives in France was markedly impacted by the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under the age of 25 years were the most substantially impacted. Ensuring access to contraceptive methods during health emergencies must be a public health policy priority.
The COVID-19 pandemic strongly impacted the dispensing of contraceptives in France with varying degrees of decreased dispensing according to the type of contraceptive, the age-group and the level of pandemic-related restrictions. The impact of these restrictions on unintended pregnancy at the population level remains undetermined.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/j.contraception.2021.12.002</identifier><identifier>PMID: 34971603</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Communicable Disease Control ; Contraception - methods ; Contraception, Postcoital ; Contraceptive Agents, Female ; Contraceptive methods ; COVID-19 ; Female ; Gynecology and obstetrics ; Healthcare access ; Human health and pathology ; Humans ; Infant ; Levonorgestrel ; Life Sciences ; Original ; Pandemics ; Pregnancy ; Reproductive health ; Santé publique et épidémiologie ; SARS-CoV-2 ; Sexual Health ; Young Adult</subject><ispartof>Contraception (Stoneham), 2022-04, Vol.108, p.50-55</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>Attribution - NonCommercial - NoDerivatives</rights><rights>2021 The Authors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93</citedby><cites>FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93</cites><orcidid>0000-0001-8687-9092 ; 0000-0002-8079-4263 ; 0000-0003-4586-4366 ; 0000-0002-8393-4217 ; 0000-0001-7646-3667 ; 0000-0003-2017-7041</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34971603$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03673652$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Roland, Noémie</creatorcontrib><creatorcontrib>Drouin, Jérôme</creatorcontrib><creatorcontrib>Desplas, David</creatorcontrib><creatorcontrib>Duranteau, Lise</creatorcontrib><creatorcontrib>Cuenot, François</creatorcontrib><creatorcontrib>Dray-Spira, Rosemary</creatorcontrib><creatorcontrib>Weill, Alain</creatorcontrib><creatorcontrib>Zureik, Mahmoud</creatorcontrib><title>Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months).
We conducted a national register-based study by extracting all reimbursements of oral contraceptives (OC), emergency contraception (EC), intrauterine devices (IUD), and implants from the French National Health Insurance database (SNDS), which includes and covers 99.5% of the French population, in 2018, 2019, 2020 and from January 1, 2021 to April30, 2021. We calculated the expected use of contraceptives in 2020 and 2021 in the absence of the pandemic, based on 2018 and 2019 usage and taking annual trends into account. We assessed the difference between observed and expected dispensing rates by contraceptive type and by age-group (≤18 years old, 18< age ≤25, 25< age ≤35, >35).
Dispensing of all contraceptives decreased compared to expect dispensing numbers: −2.0% for OC, −5.3% for EC, −9.5% for LNG-IUS, −8.6% for C-IUD, and −16.4% for implant. This decrease in the dispensing of contraceptives was observed in all age-groups, but mainly concerned women under the age of 18 years (−22% for OC, −10% for EC, −37.2% for LNG-IUS, −36.4% for C-IUD, −26.4% for implant) and those aged 18 to 25 (−5.1% for OC, −11.9% for EC, −18.1% for LNG-IUS, −15.9% for C-IUD, −17.6% for implants).
Our study showed that the dispensing of contraceptives in France was markedly impacted by the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under the age of 25 years were the most substantially impacted. Ensuring access to contraceptive methods during health emergencies must be a public health policy priority.
The COVID-19 pandemic strongly impacted the dispensing of contraceptives in France with varying degrees of decreased dispensing according to the type of contraceptive, the age-group and the level of pandemic-related restrictions. The impact of these restrictions on unintended pregnancy at the population level remains undetermined.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Communicable Disease Control</subject><subject>Contraception - methods</subject><subject>Contraception, Postcoital</subject><subject>Contraceptive Agents, Female</subject><subject>Contraceptive methods</subject><subject>COVID-19</subject><subject>Female</subject><subject>Gynecology and obstetrics</subject><subject>Healthcare access</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infant</subject><subject>Levonorgestrel</subject><subject>Life Sciences</subject><subject>Original</subject><subject>Pandemics</subject><subject>Pregnancy</subject><subject>Reproductive health</subject><subject>Santé publique et épidémiologie</subject><subject>SARS-CoV-2</subject><subject>Sexual Health</subject><subject>Young Adult</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNkUFv1DAQhS0EotvCX0CWuLSHBNuJk1hISKulpSut1Atwtbz2mPUqawc7WcS_x9G2FcuJk6XxN2_evEHoPSUlJbT5sC918GNUGobRBV8ywmhJWUkIe4EWtGtFQTjtXqIFIZQUbcfqC3SZ0p4Q0grevkYXVS1a2pBqgX6tD4PSIw4Wr0IMXh1dnBI2LoFKgBmhAl-vHr6vPxdU3ODg8dlwPGXI-cwxgpU3eBrw5EfX43EHGHIhCy-HmAuzzRm9i8preINeWdUnePv4XqFvd7dfV_fF5uHLerXcFJozPhbQdZZshRBcaW1ry41VljYmL2KqCnStVWNpXTMmDFFagNLUqJYLsBy2RlRX6NNJd5i2BzAaZvO9zI4OKv6WQTl5_uPdTv4IR9m1tGZVlwVuTgK7f9rulxs510jVtFXD2ZFm9vpxWAw_J0ijPLikoe-VhzAlyRrKBW1rzjL68YTqGFKKYJ-1KZHzmeVeniUt5_wkZTKfOXe_-3ur596nu2bg9gRAzvboIMqkHeTcjYugR2mC-69BfwCE7L_V</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Roland, Noémie</creator><creator>Drouin, Jérôme</creator><creator>Desplas, David</creator><creator>Duranteau, Lise</creator><creator>Cuenot, François</creator><creator>Dray-Spira, Rosemary</creator><creator>Weill, Alain</creator><creator>Zureik, Mahmoud</creator><general>Elsevier Inc</general><general>Elsevier</general><general>The Authors. Published by Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8687-9092</orcidid><orcidid>https://orcid.org/0000-0002-8079-4263</orcidid><orcidid>https://orcid.org/0000-0003-4586-4366</orcidid><orcidid>https://orcid.org/0000-0002-8393-4217</orcidid><orcidid>https://orcid.org/0000-0001-7646-3667</orcidid><orcidid>https://orcid.org/0000-0003-2017-7041</orcidid></search><sort><creationdate>20220401</creationdate><title>Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France</title><author>Roland, Noémie ; Drouin, Jérôme ; Desplas, David ; Duranteau, Lise ; Cuenot, François ; Dray-Spira, Rosemary ; Weill, Alain ; Zureik, Mahmoud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Communicable Disease Control</topic><topic>Contraception - methods</topic><topic>Contraception, Postcoital</topic><topic>Contraceptive Agents, Female</topic><topic>Contraceptive methods</topic><topic>COVID-19</topic><topic>Female</topic><topic>Gynecology and obstetrics</topic><topic>Healthcare access</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infant</topic><topic>Levonorgestrel</topic><topic>Life Sciences</topic><topic>Original</topic><topic>Pandemics</topic><topic>Pregnancy</topic><topic>Reproductive health</topic><topic>Santé publique et épidémiologie</topic><topic>SARS-CoV-2</topic><topic>Sexual Health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roland, Noémie</creatorcontrib><creatorcontrib>Drouin, Jérôme</creatorcontrib><creatorcontrib>Desplas, David</creatorcontrib><creatorcontrib>Duranteau, Lise</creatorcontrib><creatorcontrib>Cuenot, François</creatorcontrib><creatorcontrib>Dray-Spira, Rosemary</creatorcontrib><creatorcontrib>Weill, Alain</creatorcontrib><creatorcontrib>Zureik, Mahmoud</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roland, Noémie</au><au>Drouin, Jérôme</au><au>Desplas, David</au><au>Duranteau, Lise</au><au>Cuenot, François</au><au>Dray-Spira, Rosemary</au><au>Weill, Alain</au><au>Zureik, Mahmoud</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>108</volume><spage>50</spage><epage>55</epage><pages>50-55</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>PMCID: PMC8714238</notes><abstract>To assess the impact of the COVID-19 pandemic on the use of reimbursed contraceptives in France after 15 months of the pandemic, according to age-group and updating previous data only pertaining to the first lockdown (2 months).
We conducted a national register-based study by extracting all reimbursements of oral contraceptives (OC), emergency contraception (EC), intrauterine devices (IUD), and implants from the French National Health Insurance database (SNDS), which includes and covers 99.5% of the French population, in 2018, 2019, 2020 and from January 1, 2021 to April30, 2021. We calculated the expected use of contraceptives in 2020 and 2021 in the absence of the pandemic, based on 2018 and 2019 usage and taking annual trends into account. We assessed the difference between observed and expected dispensing rates by contraceptive type and by age-group (≤18 years old, 18< age ≤25, 25< age ≤35, >35).
Dispensing of all contraceptives decreased compared to expect dispensing numbers: −2.0% for OC, −5.3% for EC, −9.5% for LNG-IUS, −8.6% for C-IUD, and −16.4% for implant. This decrease in the dispensing of contraceptives was observed in all age-groups, but mainly concerned women under the age of 18 years (−22% for OC, −10% for EC, −37.2% for LNG-IUS, −36.4% for C-IUD, −26.4% for implant) and those aged 18 to 25 (−5.1% for OC, −11.9% for EC, −18.1% for LNG-IUS, −15.9% for C-IUD, −17.6% for implants).
Our study showed that the dispensing of contraceptives in France was markedly impacted by the COVID-19 pandemic. Prescriptions for long-acting contraceptive use and women under the age of 25 years were the most substantially impacted. Ensuring access to contraceptive methods during health emergencies must be a public health policy priority.
The COVID-19 pandemic strongly impacted the dispensing of contraceptives in France with varying degrees of decreased dispensing according to the type of contraceptive, the age-group and the level of pandemic-related restrictions. The impact of these restrictions on unintended pregnancy at the population level remains undetermined.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34971603</pmid><doi>10.1016/j.contraception.2021.12.002</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-8687-9092</orcidid><orcidid>https://orcid.org/0000-0002-8079-4263</orcidid><orcidid>https://orcid.org/0000-0003-4586-4366</orcidid><orcidid>https://orcid.org/0000-0002-8393-4217</orcidid><orcidid>https://orcid.org/0000-0001-7646-3667</orcidid><orcidid>https://orcid.org/0000-0003-2017-7041</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0010-7824 |
| ispartof | Contraception (Stoneham), 2022-04, Vol.108, p.50-55 |
| issn | 0010-7824 1879-0518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8714238 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Adolescent Adult Communicable Disease Control Contraception - methods Contraception, Postcoital Contraceptive Agents, Female Contraceptive methods COVID-19 Female Gynecology and obstetrics Healthcare access Human health and pathology Humans Infant Levonorgestrel Life Sciences Original Pandemics Pregnancy Reproductive health Santé publique et épidémiologie SARS-CoV-2 Sexual Health Young Adult |
| title | Impact of Coronavirus disease 2019 (COVID-19) on contraception use in 2020 and up until the end of April 2021 in France |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T05%3A31%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Coronavirus%20disease%202019%20(COVID-19)%20on%20contraception%20use%20in%202020%20and%20up%20until%20the%20end%20of%20April%202021%20in%20France&rft.jtitle=Contraception%20(Stoneham)&rft.au=Roland,%20No%C3%A9mie&rft.date=2022-04-01&rft.volume=108&rft.spage=50&rft.epage=55&rft.pages=50-55&rft.issn=0010-7824&rft.eissn=1879-0518&rft_id=info:doi/10.1016/j.contraception.2021.12.002&rft_dat=%3Cproquest_pubme%3E2615917452%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c525t-e88f0b9995accf4f5dfaf16d079d33ec4ca6f144229d0ac9eac1da759ef5ebd93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2615917452&rft_id=info:pmid/34971603&rfr_iscdi=true |